Childhood Hemolytic Uremic Syndrome, United Kingdom and Ireland

Overview

Journal Emerg Infect Dis

Specialty Infectious Diseases

Date 2005 Apr 15

PMID 15829199

Citations 67

Authors

Richard M Lynn

Sarah J OBrien

C Mark Taylor

Goutam K Adak

Henrik Chart

Tom Cheasty

John E Coia

Iain A Gillespie

Mary E Locking

William J Reilly

Henry R Smith

Aoife Waters

Geraldine A Willshaw

Affiliations

Soon will be listed here.

Abstract

We conducted prospective surveillance of childhood hemolytic uremic syndrome (HUS) from 1997 to 2001 to describe disease incidence and clinical, epidemiologic and microbiologic characteristics. We compared our findings, where possible, with those of a previous study conducted from 1985 to 1988. The average annual incidence of HUS for the United Kingdom and Ireland (0.71/100,000) was unchanged from 1985 to 1988. The overall early mortality had halved, but the reduction in mortality was almost entirely accounted for by improved outcome in patients with diarrhea-associated HUS. The principal infective cause of diarrhea-associated HUS was Shiga toxin-producing Escherichia coli O157 (STEC O157), although in the 1997-2001 survey STEC O157 phage type (PT) 21/28 had replaced STEC O157 PT2 as the predominant PT. The risk of developing diarrhea-associated HUS was significantly higher in children infected with STEC O157 PT 2 and PT 21/28 compared with other PTs. Hypertension as a complication of HUS was greatly reduced in patients with diarrhea-associated HUS.

Citing Articles

Hemolytic Uremic Syndrome: A COVID-19 Vaccine Reaction Case Report.

Aku T, Dordoye E, Apraku T, Gyamera A, Yamoah P, Adjei P Niger Med J. 2024; 64(6):846-850.

PMID: 38979048 PMC: 11227635. DOI: 10.60787/nmj-64-6-343.

Electroanalytical Platform for Rapid O157:H7 Detection in Water Samples.

Mishra K, Dhamu V, Jophy C, Muthukumar S, Prasad S Biosensors (Basel). 2024; 14(6).

PMID: 38920602 PMC: 11201563. DOI: 10.3390/bios14060298.

Prevalence of Shiga Toxin-Producing O157 in Wild Scottish Deer with High Human Pathogenic Potential.

Fitzgerald S, Mitchell M, Holmes A, Allison L, Chase-Topping M, Lupolova N Animals (Basel). 2023; 13(17).

PMID: 37685059 PMC: 10486872. DOI: 10.3390/ani13172795.

Haemolytic uraemic syndrome in children England, Wales, Northern Ireland, and Ireland: A prospective cohort study.

Byrne L, Douglas A, Launders N, Godbole G, Lynn R, Inward C Epidemiol Infect. 2023; 151:e160.

PMID: 37655611 PMC: 10600734. DOI: 10.1017/S0950268823001413.

Eculizumab in STEC-HUS: a paradigm shift in the management of pediatric patients with neurological involvement.

Wildes D, Harvey S, Costigan C, Sweeney C, Twomey E, Awan A Pediatr Nephrol. 2023; 39(1):315-324.

PMID: 37491519 DOI: 10.1007/s00467-023-06102-w.

References

Fitzpatrick M . Haemolytic uraemic syndrome and E coli O157. BMJ. 1999; 318(7185):684-5. PMC: 1115131. DOI: 10.1136/bmj.318.7185.684. View

Elliott E, Robins-Browne R, OLoughlin E, Bennett-Wood V, Bourke J, Henning P . Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features. Arch Dis Child. 2001; 85(2):125-31. PMC: 1718875. DOI: 10.1136/adc.85.2.125. View

Willshaw G, Cheasty T, Smith H, OBrien S, Adak G . Verocytotoxin-producing Escherichia coli (VTEC) O157 and other VTEC from human infections in England and Wales: 1995-1998. J Med Microbiol. 2001; 50(2):135-142. DOI: 10.1099/0022-1317-50-2-135. View

Chart H, Smith H, Scotland S, Rowe B, Milford D, Taylor C . Serological identification of Escherichia coli O157:H7 infection in haemolytic uraemic syndrome. Lancet. 1991; 337(8734):138-40. DOI: 10.1016/0140-6736(91)90801-u. View

Chart H, Jenkins C . The serodiagnosis of infections caused by Verocytotoxin-producing Escherichia coli. J Appl Microbiol. 1999; 86(5):731-40. DOI: 10.1046/j.1365-2672.1999.00766.x. View

Cornu G, Proesmans W, Dediste A, Jacobs F, Van De Walle J, Mertens A . Hemolytic uremic syndrome in Belgium: incidence and association with verocytotoxin-producing Escherichia coli infection. Clin Microbiol Infect. 2002; 5(1):16-22. DOI: 10.1111/j.1469-0691.1999.tb00093.x. View

Ostroff S, Tarr P, Neill M, Lewis J, Kobayashi J . Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis. 1989; 160(6):994-8. DOI: 10.1093/infdis/160.6.994. View

Boerlin P, McEwen S, Wilson J, Johnson R, Gyles C . Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J Clin Microbiol. 1999; 37(3):497-503. PMC: 84443. DOI: 10.1128/JCM.37.3.497-503.1999. View

Kleanthous H, Smith H, Scotland S, GROSS R, Rowe B, Taylor C . Haemolytic uraemic syndromes in the British Isles, 1985-8: association with verocytotoxin producing Escherichia coli. Part 2: Microbiological aspects. Arch Dis Child. 1990; 65(7):722-7. PMC: 1792459. DOI: 10.1136/adc.65.7.722. View

10.

Verity C, Preece M . Surveillance for rare disorders by the BPSU. The British Paediatric Surveillance Unit. Arch Dis Child. 2002; 87(4):269-71. PMC: 1763054. DOI: 10.1136/adc.87.4.269. View

11.

Dundas S, Todd W, Stewart A, Murdoch P, Chaudhuri A, Hutchinson S . The central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis. 2001; 33(7):923-31. DOI: 10.1086/322598. View

12.

Milford D, Taylor C, Guttridge B, Hall S, Rowe B, Kleanthous H . Haemolytic uraemic syndromes in the British Isles 1985-8: association with verocytotoxin producing Escherichia coli. Part 1: Clinical and epidemiological aspects. Arch Dis Child. 1990; 65(7):716-21. PMC: 1792437. DOI: 10.1136/adc.65.7.716. View

13.

. Vero cytotoxin producing Escherichia coli: which specimens should be tested?. Commun Dis Rep CDR Wkly. 1995; 5(31):147. View

14.

Haeghebaert S, Vaillant V, Decludt B, Grimont P . Surveillance of haemolytic uraemic syndrome in children under 15 years of age in France in 1998. Euro Surveill. 2003; 5(6):68-73. DOI: 10.2807/esm.05.06.00032-en. View

15.

Gerber A, Karch H, Allerberger F, Verweyen H, Zimmerhackl L . Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis. 2002; 186(4):493-500. DOI: 10.1086/341940. View

16.

Banatvala N, Griffin P, Greene K, Barrett T, Bibb W, Green J . The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis. 2001; 183(7):1063-70. DOI: 10.1086/319269. View

17.

Tozzi A, Caprioli A, Minelli F, Gianviti A, De Petris L, Edefonti A . Shiga toxin-producing Escherichia coli infections associated with hemolytic uremic syndrome, Italy, 1988-2000. Emerg Infect Dis. 2003; 9(1):106-8. PMC: 2873761. DOI: 10.3201/eid0901.020266. View